-
- Joan B. Mannick
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
-
- Giuseppe Del Giudice
- Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
-
- Maria Lattanzi
- Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
-
- Nicholas M. Valiante
- Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA.
-
- Jens Praestgaard
- Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
-
- Baisong Huang
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
-
- Michael A. Lonetto
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
-
- Holden T. Maecker
- Novartis Pharmaceuticals Corporation, CH-4002 Basel, Switzerland.
-
- John Kovarik
- Stanford University School of Medicine, Stanford, CA 94305–5124, USA.
-
- Simon Carson
- Southern Clinical Trials, Christchurch 8024, New Zealand.
-
- David J. Glass
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
-
- Lloyd B. Klickstein
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
説明
<jats:p>mTOR inhibition by RAD001 improves immune responses in elderly volunteers receiving an influenza vaccination.</jats:p>
収録刊行物
-
- Science Translational Medicine
-
Science Translational Medicine 6 (268), 268ra179-, 2014-12-24
American Association for the Advancement of Science (AAAS)